Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Researchers review Real-World use of avelumab in advanced bladder cancer

NCT ID NCT06412848

Knowledge-focused Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 2 times

Summary

This study reviews medical records of 360 Japanese patients with advanced bladder cancer who received avelumab as a maintenance treatment after initial chemotherapy. The goal is to understand patient characteristics, treatment patterns, and outcomes like survival and tumor response. No new treatments are given; it simply observes what happened in real-world practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

360 people

The number who actually took part.

Started

May 2024

Finished

Jun 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants with locally advanced/metastatic Urothelial Carcinoma

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants diagnosed with locally advanced/metastatic urothelial carcinoma (la/m UC) before receiving avelumab first line maintenance therapy * Participants with la/m UC (irrespective of tumor histology) whose disease has not progressed (ongoing stable disease, partial response, or complete response) following completion of first line PBCT and who has been treated with avelumab * Participants who has been started avelumab first line maintenance therapy for la/m UC from 24 Feb 2021 (date of approval for UC) to 6 months before the date of approval of implementation of this study at each site * Participants aged \>= 18 years old at index date * Other protocol defined inclusion criteria could apply Exclusion Criteria: * Participant participated in a clinical trial in la/m UC during the study periods.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Urothelial carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

transitional cell carcinoma urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Urothelial carcinoma

Contacts and locations

Locations

  • Akita University Hospital

    Akita, 010-0041, Japan

  • Ehime University Hospital

    Tōon, Ehime, 791-0295, Japan

  • Hirosaki University Hospital

    Hirosaki, Aomori, 036-8563, Japan

  • Hokkaido University Hospital

    Sapporo, Hokkaido, 060-8648, Japan

  • Iwate Medical University Hospital

    Shiwa-gun, Iwate, 028-3695, Japan

  • Juntendo University Hospital

    Bunkyō City, Tokya, 113-0033, Japan

  • Kagawa University Hospital

    Kita-gun, Kagawa-ken, 761-0793, Japan

  • Kindai University Hospital

    Sayama, Osaka, 589-8511, Japan

  • Kitasato University Hospital

    Sagamihara, Kanagawa, 252-0374, Japan

  • Kobe University Hospital

    Kobe, Hyōgo, 650-0017, Japan

  • Kumamoto University Hospital

    Kumamoto, 860-8556, Japan

  • Kurume University Hospital

    Kurume, Fukuoka, 830-0011, Japan

  • Kyoto University Hospital

    Kyoto, 606-8507, Japan

  • Kyushu Cancer Center

    Fukuoka, 811-1347, Japan

  • Nara Medical University Hospital

    Kashihara, Nara, 634-8522, Japan

  • National Cancer Center Hospital

    Chuo-ku, Tokyo, 104-0045, Japan

  • Nippon Medical School Hospital

    Bunkyo-ku, Tokyo, 113-8603, Japan

  • Osaka International Cancer Institute

    Osaka, 540-0008, Japan

  • Saitama Medical University International Medical Center

    Hidaka, Saitama, 350-1298, Japan

  • Sapporo Medical University Hospital

    Sapporo, Hokkaido, 060-8648, Japan

  • St. Marianna University Hospital

    Kawasaki, Kanagawa, 216-8511, Japan

  • Teikyo University Hospital

    Itabashi-ku, Tokyo, 173-8606, Japan

  • Tokushima University Hospital

    Tokushima, 770-0042, Japan

  • Toyama University Hospital

    Toyama, 930-0194, Japan

  • University Hospital Kyoto Prefectural University of Medicine

    Kyoto, 602-8566, Japan

  • Yamagata University Hospital

    Yamagata, 9902331, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.